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INTRODUCTION:  Carcinosarcoma  is  a rare malignant  biphasic  tumor  which  has  sarcomatous  and  carcino-
matous components.  Stomach  localization  is very  rare.  We  discuss  the  diagnosis,  follow-up  and  treatment
of patients  diagnosed  with  gastric  carcinosarcoma  in  company  with  the  literature  review.
PRESENTATION  OF  CASE:  A  73-year-old  white  male  patient  applied  to hospital  with  dyspeptic  complaints
lasting  for  2 months.  His  endoscopic  examination  revealed  an ulcero-vegetating  mass  in the  cardiac  region
of his  stomach.  Total  gastrectomy  and  D2 lymph  node  dissection  were  performed  for the  patient.  In
the  pathologic  evaluation,  the  tumor  was  found  consistent  with  Stage  IIA stomach  adenocarcinoma  in
accordance  with  AJCC  (7edt,  2010)  classiﬁcation.  Pathologic  specimen  was  reevaluated  by an  expert
pathologist  for the  patient  with  progression  and  liver  metastasis  under  adjuvant  chemotherapy  and
concomitant  radiotherapy.  The  new  pathology  was  consistent  with  gastric  carcinosarcoma,  and  90% of the
tumor was  identiﬁed  as  osteosarcoma  whereas  10%  was  identiﬁed  as  carcinoma.  Cisplatin  doxorubicine-
based  chemotherapy  was  given  considering  the  fact that sarcomatous  component  was  dominant.1 The
patient  was  given  3 courses  of chemotherapy.  However,  as the patient  showed  progression  under  therapy,
he died  after  14  months  of the  diagnosis.
DISCUSSION:  Gastric  carcinosarcoma  is a very  rare  and  clinically  aggressive  malignancy.  Recurrence  is
likely  to occur  with  a rate  of  more  than  50%  in  patients  who  have  undergone  resection  within  the  ﬁrst
year  following  surgery,  and  overall  survival  time  is 10–15  months.
CONCLUSION:  In  refractory  gastric  carcinoma  cases  with  rapid  progression,  we suggest  that  gastric  carci-
nosarcoma  with  biphasic  component  should  be taken  into  consideration  and  the  pathological  evaluation
n  exp
ical Ashould  be performed  by  a
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. Introduction
Carcinosarcoma is a rare malignant biphasic tumor which has
arcomatous and carcinomatous components together.2 It typically
evelops in the uterus, eosophagus, and breast while stomach local-
zation is very rarely seen in carcinosarcoma cases.3–6 Although the
umor may  be polypoid, exophytic and endophytic it is generally
lceroinﬁltrative in structure and large in size.5,7,8 It is diagnosed
mmunohistochemically.9,10 Its treatment involves radical, subto-
al or total gastrectomy.11,12
. Case
A 73-year-old white male patient applied to hospital with dys-
eptic complaints lasting for 2 months. His endoscopic examination
evealed an ulcero-vegetating mass of 5–6 cm in the cardiac region
lling the fundus. Evaluation of preoperative thoracal CT revealed mass lesion causing an asymmetrical thickening of the gastric
all without any detected distant metastasis. Fine needle biopsy of
he mass conducted under the guidance of upper tract gastroscopy
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suggested the diagnosis of gastric adenocarcinoma. Total gastrec-
tomy and D2 lymph node dissection were performed for the patient.
In his pathological examination, a nonmetastatic subserosal tumor
was detected during the sampling of 23 lymph nodes. The tumor
was found consistent with T3 N0 (Stage IIA) stomach adenocarci-
noma in accordance with AJCC (7edt, 2010) classiﬁcation. Tumor
marker level was  below CEA 3.78, CA 19.9 2. Thoracic, abdominal,
and pelvic computed tomography revealed no distant metastasis.
The patient diagnosed with Stage II stomach adenocarcinoma was
given adjuvant 5 ﬂuorouracil, calcium folinate chemotherapy and
concomitant radiotherapy in the Macdonald protocol.13
The abdominal computed tomography showed that the size of
the liver was above the normal, and revealed multiple metastatic
lesions that were in afﬁnity with each other and diffuse in the
left lobe of the liver in patient who developed left side pain
(Fig. 1). Upon progression under treatment, revision was required
for pathological representations. Pathologic specimen was reevalu-
ated by an expert pathologist. The tumor was located in the cardia;
had a size of 12 cm × 9.5 cm × 5 cm;  was  fungative, expansive with
20% massive necrosis area in the center (Fig. 2a–c). It had totally
Open access under CC BY-NC-ND license.two components which were epithelial and mesenchymal. The
carcinomatous component was  reported as tubular and indifferen-
tial type adenocarcinoma; whereas, the sarcomatous component
was reported as osterosarcoma. Ninety percent of the tumor was
BY-NC-ND license.
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dentiﬁed as osteosarcoma whereas 10% was identiﬁed as carci-
oma (Fig. 3a–c). The sarcomatous component stained positively
or vimentin; further, an intermediate component was also avail-
ble that was negative for keratin and vimentin. Lymphovascular
nvasion was positive. Assessment using only light microscopic
Fig. 2. (a–c) Macroscopic app
ig. 3. (a) 4785/09-HEx100, (b) 4875/09-HEx200, (c) 4875/09-HEx200. Malign osteoid 
ifferentiated adenocarcinoma component of tumor.PEN  ACCESS
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criteria, inability to evaluate ﬁeld of the tumoral area completely,
and misleading impact of histopathologic examination of the ﬁne
needle biopsy material were suggested as the reasons for the mis-
diagnosis made after the ﬁrst evaluation (see Table 1).
Considering the fact that sarcomatous component was domi-
nant, metastatic osteosarcoma therapy was  planned and cisplatin
doxorubicine-based chemotherapy was given to the patient diag-
nosed with metastatic stomach carcinosarcoma.1 However, the
patient died after 14 months of diagnosis in the 3rd month of the
therapy.
3. Discussion
Carcinosarcoma is a rare biphasic tumor which has epithelial
and mesenchymal malignant tumors together.6,12 The majority of
gastric carcinosarcoma cases is comprised male population from
Japan and who are above 60-years-old.2,7,9 It typically develops in
the uterus, eosophagus, and breast while stomach localization is
very rarely seen in carcinosarcoma cases.3–6 Although the tumor
may  be polypoid, exophytic and endophytic it is generally ulceroin-
ﬁltrative in structure and large in size.5,7,8
Although the carcinomatous component usually consists
of intestinal adenocarcinoma, there may be endocrine and
neuroendocrine components. The sarcomatous component
may  present myeloblastic, condroblastic, lipoid or osteoblastic
differentiation.2,5,9,10,15 The gold standard of diagnosis is immuno-
histochemical analysis. The major speciﬁc markers used in the
diagnosis are CEA, EMA, chromogranin A, pancreozymin, CD 56,
and synaptophysin for the carcinomatous component; demsin
and vimentin for the sarcomatous component.9,10 Carcinosarcoma
earance of the tumor.
production by tumoral osteoblasts in osteosarcomatous area next to moderately
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Table 1
Prior reported cases gastrit carcinosarcoma.
No. Author Year Age Sex Size (cm) Treatment Outcome
1 Ashide4 1995 74 M 12 Resection NED (7 year)
2 Nakayama et al.2 1997 69 M 20 Resection DOD (1 month)
3 Matsukuma24 1997 74 F 15 Resection DOD (5.5 month)
4  Inoue25 1998 74 F 7.8 Resection DOD (10 month)
5  Tsuneyama13 1999 63 M 7 Resection NED (10 month)
6  Sato et al.10 2001 67 F 8 Resection NED (11 month)
7  Teramachi et al.9 2003 62 M 10 Resection NED (20 month)
8 Yamazaki5 2003 56 M 9 Resection DOD (2 month)
9 Kuroda  et al.15 2006 59 M 9.2 Resection ND
10 Yoshıyukı22 2007 70 F 21 Palliative care DED (16 day)
11  Current study 2012 73 M 12 Resection DOD (14 month)
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1OD: died of disease, ND: not described, NED: alive no evidence disease.
etastasis may  consist of only the carcinomatous or only the
arcomatous component as well as carcinosarcoma.7 The surgical
reatment of gastric cancer has been a matter of extensive research.
arcinosarcoma treatment consists of radical, subtotal or total
astrectomy11,12 and in the current era D2 gastrectomy is accepted
s the standard operation, with an excellent cure rate and low loco
egional recurrence.16 More aggressive extended D3 gastrectomy
as been practiced in certain patients with survival and disease-
ree beneﬁts, especially for advanced gastric cancer.17,18 On the
ontrary, D1 gastrectomy has been considered to be sufﬁcient for
ucosal cancer.19
Chemotherapy and radiotherapy have not been deﬁned yet.
lthough uncertain, methionine/valine-depleted enteral nutrition
as been reported to contribute to tumor reduction.20 Although
he prognosis of gastric carcinosarcoma is more poor compared
o that of other gastric carcinomas, the overall survival time is
0–15 months with a possibility of relapse over 50% within the ﬁrst
ear following surgery in gastric carcinosarcoma cases.9,10,21
Gastric carcinosarcoma is a very rare and clinically aggressive
alignancy. Recurrence is likely to occur with a rate of more
han 50% in patients who have undergone gastric resection within
he ﬁrst year following surgery with an overall survival time of
0–15 months.9,10,21 In the differential diagnosis of refractory gas-
ric carcinoma cases with rapid progression, we suggest that gastric
arcinosarcoma should be taken into consideration; the patholog-
cal evaluation should be performed by an expert pathologist; and
umor specimen should be evaluated in details.
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